Aslan Pharmaceuticals initiated with a Buy at BTIG. BTIG analyst Robert Hazlett initiated Aslan Pharmaceutical with a Buy rating and a price target of $16. The analyst notes that this “innovative oncology therapeutics” company has “important pivotal readouts” coming for its Varlitinib program as the management drives its clinical development in Asia. Hazlett estimates that global peak revenue for the treatment in biliary tract cancer and gastric cancer could reach $1.3B, as both of those programs have readouts in the second half of this year / 2019 respectively. The analyst also sees “material promise” for Aslan’s oral DHODH inhibitor in mid-stage development in AML, with phase 2 data readout anticipated for the second half of 2018 as well.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.